Authors
Latest:
It's Time to Get Serious About New Rules for Handling Hazardous DrugsImplementation of new standards for handling hazardous drugs in healthcare facilities is coming closer to reality now that the calendar has flipped to 2019.
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
Hedgehog Signal Inhibition Hope or Hype?Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.
Latest:
Dr. Graff Discusses the Treatment of Prostate CancerJulie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.
Latest:
Dr. Gralow on Future Challenges in Cancer Care in the Post–COVID-19 EraJulie R. Gralow, MD, discusses future challenges in cancer care following the COVID-19 pandemic.
Latest:
Combining Chemo With mTOR Inhibitors Shows Promise in pNETSCombining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.
Latest:
Dr Vose on the Investigation of Epcoritamab in Relapsed/Refractory Follicular LymphomaJulie M. Vose, MD, MBA, discusses the investigation of epcoritamab in relapsed/refractory follicular lymphoma.
Latest:
Dr. Graff on Combination Regimens With Checkpoint Inhibitors in mCRPCJulie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.
Latest:
Clinical Pearls and Closing Thoughts on NSCLC Treatment LandscapeClosing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Latest:
Dr. Gralow on the Integration on Precision Medicine Into OncologyJulie R. Gralow, MD, discusses the integration of precision medicine into oncology.
Latest:
Dr. Nangia on Challenges Facing Hair Loss Treatment for Breast CancerJulie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses hair loss prevention treatment for patients with breast cancer.
Latest:
Dr. Nangia Discusses the Logistics of Implementing a Scalp Cooling SystemJulie R. Nangia, MD, assistant professor of medicine, Baylor College of Medicine, discusses some logistical factors that oncologists and health care providers should know regarding implementing a scalp cooling system.
Latest:
Baylor Team Helps Establish Scalp-Cooling Benefits for Breast Cancer PatientsSupported by research, there have been recent developments in using scalp cooling to combat chemotherapy-induced alopecia for patients with breast cancer.
Latest:
Should Physicians Friend or Unfriend Social Media? 'It's Complicated'Compared to other industries, the medical profession has been late in recognizing the many benefits of social media. In the past few years, it has entered into an uneasy relationship with the new medium.
Latest:
Dr. Barker on Cord Blood TransplantationJuliet N. Barker, MBSS, director, Cord Blood Transplantation Program, Memorial Sloan-Kettering Cancer Center, discusses using double-unit cord blood transplantation with a haplo-identical donor in patients with hematologic malignancies.
Latest:
Dr. Chavez on Blinatumomab in ALLJulio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).
Latest:
Biology and Management of Diffuse Large B-cell LymphomaRecent statistics show lymphoid malignancies to be the fifth most common cause of cancer-related death in the United States.
Latest:
Epigenetic Variations in Prostate Tumors May Determine Choice Between Definitive Treatment and Active SurveillanceProstate cancer is the most common cancer and second leading cause of cancer mortality in American men. Nevertheless, it is estimated that only 3% of the patients will die because of their cancer, while the majority will die of competing causes.
Latest:
Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPCJun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.
Latest:
Dr. Grilley-Olson on Treating Patients Based on Molecular ProfileJuneko Grilley-Olson, MD, assistant professor, UNC-Chapel Hill, Clinical Research, Thoracic Oncology Program, Head and Neck Oncology Program, Bone and Soft Tissue Oncology Program, UNC Lineberger Comprehensive Cancer Center, discusses treating patients with cancer based on their molecular profile.
Latest:
Anti-Proliferative Activity of Eribulin in Select Sarcoma Cell LinesJunji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.
Latest:
Dr. Gainor on the Evolving Lung Cancer ArmamentariumJustin F. Gainor, MD, discusses the evolving lung cancer armamentarium.
Latest:
Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung CancerJustin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.
Latest:
Justin Balko on JAK2 Amplification in TNBCJustin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.
Latest:
Dr. Baker on Integrating Palliative Care into Pediatric OncologyJustin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses integrating palliative care into the treatment of pediatric oncology.
